CRISPR Could Change The World, But Right Now $90 Million Is Enough – Forbes
Forbes |
CRISPR Could Change The World, But Right Now $90 Million Is Enough
Forbes There's nothing like a business development deal to give a sense of scale to a mountain of scientific hype. That's what happened this morning, when Allergan, the eye-drug and Botox maker, signed a deal with Editas Medicine, which owns licenses to the … Allergan, Editas partner on CRISPR tech in eye diseases Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseases Editas and Allergan Partner on Multiple CRISPR Eye Disease Programs |
